FGF7/FGFR2–JunB signalling counteracts the effect of progesterone in luminal breast cancer

We have recently demonstrated that fibroblast growth factor receptor 2 (FGFR2)‐mediated signalling alters progesterone receptor (PR) activity and response of oestrogen receptor α (ER)‐positive (ER+) breast cancer (BCa) cell lines to anti‐ER agents. Little is known about whether the crosstalk between...

Descripción completa

Detalles Bibliográficos
Autores principales: Mieczkowski, Kamil, Kitowska, Kamila, Braun, Marcin, Galikowska‐Bogut, Barbara, Gorska‐Arcisz, Monika, Piasecka, Dominika, Stawiski, Konrad, Zaczek, Anna J., Nejc, Dariusz, Kordek, Radzisław, Romanska, Hanna M., Sadej, Rafal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348598/
https://www.ncbi.nlm.nih.gov/pubmed/35726195
http://dx.doi.org/10.1002/1878-0261.13274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348598/
https://www.ncbi.nlm.nih.gov/pubmed/35726195
http://dx.doi.org/10.1002/1878-0261.13274

Ejemplares similares